Samsung Bioepis Gets Second US Denosumab Biosimilar As Competitors Line Up

Korean Developer Also Receives Formal EU Approval For Prolia/Xgeva Rival

 
• By Dave Wallace
  
Samsung Bioepis is second to receive FDA approval for denosumab biosimilars (Shutterstock)

More from Biosimilars

More from Business